These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 8261579)
1. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Levêque D; Quoix E; Dumont P; Massard G; Hentz JG; Charloux A; Jehl F Cancer Chemother Pharmacol; 1993; 33(2):176-8. PubMed ID: 8261579 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. Levêque D; Jehl F; Quoix E; Monteil H Xenobiotica; 1993 Nov; 23(11):1325-33. PubMed ID: 8310715 [TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. Levêque D; Jehl F; Quoix E; Breillout F J Clin Pharmacol; 1992 Dec; 32(12):1096-8. PubMed ID: 1336784 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Furuse K; Kubota K; Kawahara M; Ogawara M; Kinuwaki E; Motomiya M; Nishiwaki Y; Niitani H; Sakuma A Lung Cancer; 1994 Dec; 11(5-6):385-91. PubMed ID: 7704495 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Depierre A; Lemarie E; Dabouis G; Garnier G; Jacoulet P; Dalphin JC Am J Clin Oncol; 1991 Apr; 14(2):115-9. PubMed ID: 1851385 [TBL] [Abstract][Full Text] [Related]
7. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844 [TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. van Tellingen O; Kuijpers AV; Beijnen JH; Nooijen WJ; Bult A Invest New Drugs; 1993; 11(2-3):141-50. PubMed ID: 8262726 [TBL] [Abstract][Full Text] [Related]
10. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Goa KL; Faulds D Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948 [TBL] [Abstract][Full Text] [Related]
11. Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Levêque D; Merle-Melet M; Bresler L; Didelot JP; Aymard JP; Wihlm J; Jehl F Cancer Chemother Pharmacol; 1993; 32(6):487-90. PubMed ID: 8258199 [TBL] [Abstract][Full Text] [Related]
12. Vinorelbine: a novel vinca alkaloid. Toso C; Lindley C Am J Health Syst Pharm; 1995 Jun; 52(12):1287-304; quizz 1340-1. PubMed ID: 7656116 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. Tsuruo T; Inaba M; Tashiro T; Yamori T; Ohnishi Y; Ashizawa T; Sakai T; Kobayashi S; Gomi K Anticancer Drugs; 1994 Dec; 5(6):634-40. PubMed ID: 7888700 [TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703 [TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Evans WK; Le Chevalier T Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606 [TBL] [Abstract][Full Text] [Related]
16. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091 [TBL] [Abstract][Full Text] [Related]
17. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Stuckler D; Singhal J; Singhal SS; Yadav S; Awasthi YC; Awasthi S Cancer Res; 2005 Feb; 65(3):991-8. PubMed ID: 15705900 [TBL] [Abstract][Full Text] [Related]
18. The clinical pharmacokinetics of vinorelbine (Navelbine). Wargin WA; Lucas VS Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765 [TBL] [Abstract][Full Text] [Related]
19. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671 [TBL] [Abstract][Full Text] [Related]
20. Vinorelbine for non-small cell lung cancer. Piccirillo MC; Daniele G; Di Maio M; Bryce J; De Feo G; Del Giudice A; Perrone F; Morabito A Expert Opin Drug Saf; 2010 May; 9(3):493-510. PubMed ID: 20350282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]